ArticlePloS one2013
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma.Research square · 2025Article
- Protein Kinase D3 (PKD3) Requires Hsp90 for Stability and Promotion of Prostate Cancer Cell Migration.Cells · 2023Article
- Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.Clinical genetics · 2020Review
- Therapies targeting the signal pathways of pheochromocytoma and paraganglioma.OncoTargets and therapy · 2019Article
- Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.Targeted oncology · 2018Article
- Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice.Endocrinology · 2017Article
- Effects of 17-allylamino-17-demethoxygeldanamycin on the induction of apoptosis and cell cycle arrest in HCT-116 cells.Oncology letters · 2017Article
- Heat shock proteins in the retina: Focus on HSP70 and alpha crystallins in ganglion cell survival.Progress in retinal and eye research · 2016Review
- The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Heat shock proteins: a therapeutic target worth to consider.Veterinary world · 2015Review
- Target therapy in metastatic pheochromocytoma: current perspectives and controversies.Oncology reviews · 2014Review
- Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.Endocrine-related cancer · 2014Review
- Capsaicin induces apoptosis in PC12 cells through ER stress.Oncology reports · 2014Article
- High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.PloS one · 2014Article
- Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.Current problems in cancerReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Metastatic pheochromocytoma represents one of the major clinical challenges in the field of neuroendocrine oncology. Recent molecular characterization of pheochromocytoma suggests new treatment options with targeted therapies. In this study we investigated the 90 kDa heat shock protein (Hsp90) as a potential therapeutic target for advanced pheochromocytoma. Both the first generation, natural product Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), and the second-generation synthetic Hsp90 inhibitor STA-9090 (ganetespib) demonstrated potent inhibition of proliferation and migration of pheochromocytoma cell lines and induced degradation of key Hsp90 clients. Furthermore, ganetespib induced dose-dependent cytotoxicity in primary pheochromocytoma cells. Using metastatic models of pheochromocytoma, we demonstrate the efficacy of 17-AAG and ganetespib in reducing metastatic burden and increasing survival. Levels of Hsp70 in plasma from the xenograft studies served as a proximal biomarker of drug treatment. Our study suggests that targeting Hsp90 may benefit patients with advanced pheochromocytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.